Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News Briefs: User Fee Bill, Sunshine Mobile Apps, More

This article was originally published in The Gray Sheet

Executive Summary

The House introduced a bill that would exempt device and drug user fees from sequestration cuts. CMS releases two mobile apps to help track payments required under the Sunshine law. More news.

You may also be interested in...



Regenerative Medicine Firm Cesca Therapeutics Eyeing Major Device Players

The new company, forming from the merger of ThermoGenesis and TotipotentRx, aims to use its cell processing systems and cell formulations to recast the way physicians treat various cardiovascular and orthopedic problems. It is in discussions with device firms about potential partnerships.

News Briefs: Senate Introduces User Fee Bill; Lawsuit Ends Over Conflict Minerals

Senators try to shield FDA user fees from sequestration. Court rejects business groups’ challenge to conflict minerals reporting law. More news in brief

Zoll Acquires CoAxia Assets In Bid To Revive NeuroFlo Stroke Catheter

CoAxia Inc. did not have the funds to continue after its de novo petition for the NeuroFlo catheter was rejected by FDA for acute ischemic stroke. But Zoll still sees opportunity for the device; now that it owns the technology, the firm plans to design a new pivotal trial to take before the agency.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT032236

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel